CN108728462A - H3N2 type canine influenza virus shuttle intracellular antibodies TAT-2C - Google Patents
H3N2 type canine influenza virus shuttle intracellular antibodies TAT-2C Download PDFInfo
- Publication number
- CN108728462A CN108728462A CN201810538741.3A CN201810538741A CN108728462A CN 108728462 A CN108728462 A CN 108728462A CN 201810538741 A CN201810538741 A CN 201810538741A CN 108728462 A CN108728462 A CN 108728462A
- Authority
- CN
- China
- Prior art keywords
- influenza virus
- tat
- ser
- antibody
- dog
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 45
- 241000252870 H3N2 subtype Species 0.000 title claims abstract description 33
- 241000282465 Canis Species 0.000 title claims abstract description 25
- 230000003834 intracellular effect Effects 0.000 title claims abstract description 15
- 206010022000 influenza Diseases 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims description 5
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 29
- 102000004169 proteins and genes Human genes 0.000 abstract description 21
- 238000011160 research Methods 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 8
- 101710149951 Protein Tat Proteins 0.000 abstract description 4
- 230000000840 anti-viral effect Effects 0.000 abstract description 4
- 102000037865 fusion proteins Human genes 0.000 abstract description 4
- 108020001507 fusion proteins Proteins 0.000 abstract description 4
- 238000013518 transcription Methods 0.000 abstract description 4
- 230000035897 transcription Effects 0.000 abstract description 4
- 101710154606 Hemagglutinin Proteins 0.000 abstract description 3
- 108010090054 Membrane Glycoproteins Proteins 0.000 abstract description 3
- 102000012750 Membrane Glycoproteins Human genes 0.000 abstract description 3
- 101710093908 Outer capsid protein VP4 Proteins 0.000 abstract description 3
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract description 3
- 101710176177 Protein A56 Proteins 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 3
- 238000009739 binding Methods 0.000 abstract description 3
- 230000027455 binding Effects 0.000 abstract description 3
- 239000000185 hemagglutinin Substances 0.000 abstract description 3
- 230000003472 neutralizing effect Effects 0.000 abstract description 3
- 230000037029 cross reaction Effects 0.000 abstract description 2
- 230000001900 immune effect Effects 0.000 abstract description 2
- 208000037797 influenza A Diseases 0.000 abstract description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 6
- 150000002460 imidazoles Chemical class 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000010361 transduction Methods 0.000 description 5
- 230000026683 transduction Effects 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 4
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 4
- 108010005233 alanylglutamic acid Proteins 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 108700000788 Human immunodeficiency virus 1 tat peptide (47-57) Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IGXNPQWXIRIGBF-KEOOTSPTSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IGXNPQWXIRIGBF-KEOOTSPTSA-N 0.000 description 2
- WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 2
- 108010076441 Ala-His-His Proteins 0.000 description 2
- XUCHENWTTBFODJ-FXQIFTODSA-N Ala-Met-Ala Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(O)=O XUCHENWTTBFODJ-FXQIFTODSA-N 0.000 description 2
- AWNAEZICPNGAJK-FXQIFTODSA-N Ala-Met-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(O)=O AWNAEZICPNGAJK-FXQIFTODSA-N 0.000 description 2
- ARHJJAAWNWOACN-FXQIFTODSA-N Ala-Ser-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O ARHJJAAWNWOACN-FXQIFTODSA-N 0.000 description 2
- VKKYFICVTYKFIO-CIUDSAMLSA-N Arg-Ala-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCN=C(N)N VKKYFICVTYKFIO-CIUDSAMLSA-N 0.000 description 2
- UXJCMQFPDWCHKX-DCAQKATOSA-N Arg-Arg-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(O)=O)C(O)=O UXJCMQFPDWCHKX-DCAQKATOSA-N 0.000 description 2
- AOHKLEBWKMKITA-IHRRRGAJSA-N Arg-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N AOHKLEBWKMKITA-IHRRRGAJSA-N 0.000 description 2
- MKJBPDLENBUHQU-CIUDSAMLSA-N Asn-Ser-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O MKJBPDLENBUHQU-CIUDSAMLSA-N 0.000 description 2
- UGXYFDQFLVCDFC-CIUDSAMLSA-N Asn-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O UGXYFDQFLVCDFC-CIUDSAMLSA-N 0.000 description 2
- QNFRBNZGVVKBNJ-PEFMBERDSA-N Asp-Ile-Gln Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC(=O)O)N QNFRBNZGVVKBNJ-PEFMBERDSA-N 0.000 description 2
- USNJAPJZSGTTPX-XVSYOHENSA-N Asp-Phe-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O USNJAPJZSGTTPX-XVSYOHENSA-N 0.000 description 2
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 2
- MNQMTYSEKZHIDF-GCJQMDKQSA-N Asp-Thr-Ala Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O MNQMTYSEKZHIDF-GCJQMDKQSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 2
- XZLLTYBONVKGLO-SDDRHHMPSA-N Gln-Lys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)N)N)C(=O)O XZLLTYBONVKGLO-SDDRHHMPSA-N 0.000 description 2
- MIWJDJAMMKHUAR-ZVZYQTTQSA-N Glu-Trp-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N MIWJDJAMMKHUAR-ZVZYQTTQSA-N 0.000 description 2
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 2
- PYTZFYUXZZHOAD-WHFBIAKZSA-N Gly-Ala-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CN PYTZFYUXZZHOAD-WHFBIAKZSA-N 0.000 description 2
- IWAXHBCACVWNHT-BQBZGAKWSA-N Gly-Asp-Arg Chemical compound NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IWAXHBCACVWNHT-BQBZGAKWSA-N 0.000 description 2
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 2
- PDUHNKAFQXQNLH-ZETCQYMHSA-N Gly-Lys-Gly Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)NCC(O)=O PDUHNKAFQXQNLH-ZETCQYMHSA-N 0.000 description 2
- WNZOCXUOGVYYBJ-CDMKHQONSA-N Gly-Phe-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)CN)O WNZOCXUOGVYYBJ-CDMKHQONSA-N 0.000 description 2
- LCRDMSSAKLTKBU-ZDLURKLDSA-N Gly-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CN LCRDMSSAKLTKBU-ZDLURKLDSA-N 0.000 description 2
- 101000869719 Homo sapiens Sodium-dependent phosphate transporter 2 Proteins 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 2
- AXZGZMGRBDQTEY-SRVKXCTJSA-N Leu-Gln-Met Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O AXZGZMGRBDQTEY-SRVKXCTJSA-N 0.000 description 2
- CQGSYZCULZMEDE-UHFFFAOYSA-N Leu-Gln-Pro Natural products CC(C)CC(N)C(=O)NC(CCC(N)=O)C(=O)N1CCCC1C(O)=O CQGSYZCULZMEDE-UHFFFAOYSA-N 0.000 description 2
- GPICTNQYKHHHTH-GUBZILKMSA-N Leu-Gln-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O GPICTNQYKHHHTH-GUBZILKMSA-N 0.000 description 2
- QNBVTHNJGCOVFA-AVGNSLFASA-N Leu-Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CCC(O)=O QNBVTHNJGCOVFA-AVGNSLFASA-N 0.000 description 2
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 2
- IXHKPDJKKCUKHS-GARJFASQSA-N Lys-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCCN)N IXHKPDJKKCUKHS-GARJFASQSA-N 0.000 description 2
- GQZMPWBZQALKJO-UWVGGRQHSA-N Lys-Gly-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(O)=O GQZMPWBZQALKJO-UWVGGRQHSA-N 0.000 description 2
- AIRZWUMAHCDDHR-KKUMJFAQSA-N Lys-Leu-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O AIRZWUMAHCDDHR-KKUMJFAQSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- SPSSJSICDYYTQN-HJGDQZAQSA-N Met-Thr-Gln Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCC(N)=O SPSSJSICDYYTQN-HJGDQZAQSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- XMBSYZWANAQXEV-UHFFFAOYSA-N N-alpha-L-glutamyl-L-phenylalanine Natural products OC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XMBSYZWANAQXEV-UHFFFAOYSA-N 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- BKWJQWJPZMUWEG-LFSVMHDDSA-N Phe-Ala-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 BKWJQWJPZMUWEG-LFSVMHDDSA-N 0.000 description 2
- CUMXHKAOHNWRFQ-BZSNNMDCSA-N Phe-Asp-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 CUMXHKAOHNWRFQ-BZSNNMDCSA-N 0.000 description 2
- FUAIIFPQELBNJF-ULQDDVLXSA-N Phe-Met-Lys Chemical compound CSCC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N FUAIIFPQELBNJF-ULQDDVLXSA-N 0.000 description 2
- FGWUALWGCZJQDJ-URLPEUOOSA-N Phe-Thr-Ile Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O FGWUALWGCZJQDJ-URLPEUOOSA-N 0.000 description 2
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 2
- HAAQQNHQZBOWFO-LURJTMIESA-N Pro-Gly-Gly Chemical compound OC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1 HAAQQNHQZBOWFO-LURJTMIESA-N 0.000 description 2
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 2
- QEDMOZUJTGEIBF-FXQIFTODSA-N Ser-Arg-Asp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(O)=O QEDMOZUJTGEIBF-FXQIFTODSA-N 0.000 description 2
- FMDHKPRACUXATF-ACZMJKKPSA-N Ser-Gln-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(O)=O FMDHKPRACUXATF-ACZMJKKPSA-N 0.000 description 2
- SFTZWNJFZYOLBD-ZDLURKLDSA-N Ser-Gly-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CO SFTZWNJFZYOLBD-ZDLURKLDSA-N 0.000 description 2
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 2
- GJFYFGOEWLDQGW-GUBZILKMSA-N Ser-Leu-Gln Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N GJFYFGOEWLDQGW-GUBZILKMSA-N 0.000 description 2
- YUJLIIRMIAGMCQ-CIUDSAMLSA-N Ser-Leu-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O YUJLIIRMIAGMCQ-CIUDSAMLSA-N 0.000 description 2
- AZWNCEBQZXELEZ-FXQIFTODSA-N Ser-Pro-Ser Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O AZWNCEBQZXELEZ-FXQIFTODSA-N 0.000 description 2
- OLKICIBQRVSQMA-SRVKXCTJSA-N Ser-Ser-Tyr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O OLKICIBQRVSQMA-SRVKXCTJSA-N 0.000 description 2
- 102100032419 Sodium-dependent phosphate transporter 2 Human genes 0.000 description 2
- NRUPKQSXTJNQGD-XGEHTFHBSA-N Thr-Cys-Arg Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O NRUPKQSXTJNQGD-XGEHTFHBSA-N 0.000 description 2
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 2
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 2
- KZSYAEWQMJEGRZ-RHYQMDGZSA-N Thr-Leu-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O KZSYAEWQMJEGRZ-RHYQMDGZSA-N 0.000 description 2
- MNYNCKZAEIAONY-XGEHTFHBSA-N Thr-Val-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O MNYNCKZAEIAONY-XGEHTFHBSA-N 0.000 description 2
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 2
- PKZIWSHDJYIPRH-JBACZVJFSA-N Trp-Tyr-Gln Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCC(N)=O)C(O)=O PKZIWSHDJYIPRH-JBACZVJFSA-N 0.000 description 2
- MBLJBGZWLHTJBH-SZMVWBNQSA-N Trp-Val-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 MBLJBGZWLHTJBH-SZMVWBNQSA-N 0.000 description 2
- MVFQLSPDMMFCMW-KKUMJFAQSA-N Tyr-Leu-Asn Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O MVFQLSPDMMFCMW-KKUMJFAQSA-N 0.000 description 2
- SSYBNWFXCFNRFN-GUBZILKMSA-N Val-Pro-Ser Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O SSYBNWFXCFNRFN-GUBZILKMSA-N 0.000 description 2
- WUFHZIRMAZZWRS-OSUNSFLBSA-N Val-Thr-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](C(C)C)N WUFHZIRMAZZWRS-OSUNSFLBSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010081404 acein-2 Proteins 0.000 description 2
- 108010008685 alanyl-glutamyl-aspartic acid Proteins 0.000 description 2
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 2
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 2
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 108010008355 arginyl-glutamine Proteins 0.000 description 2
- 108010069205 aspartyl-phenylalanine Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 108010078144 glutaminyl-glycine Proteins 0.000 description 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 2
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012549 training Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108010073969 valyllysine Proteins 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- RAVVEEJGALCVIN-AGVBWZICSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]hexanoyl]amino]-5-(diamino Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 RAVVEEJGALCVIN-AGVBWZICSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- UHMQKOBNPRAZGB-CIUDSAMLSA-N Ala-Glu-Met Chemical compound C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCSC)C(=O)O)N UHMQKOBNPRAZGB-CIUDSAMLSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- MMLHRUJLOUSRJX-CIUDSAMLSA-N Ala-Ser-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN MMLHRUJLOUSRJX-CIUDSAMLSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- JJHBEVZAZXZREW-LFSVMHDDSA-N Ala-Thr-Phe Chemical compound C[C@@H](O)[C@H](NC(=O)[C@H](C)N)C(=O)N[C@@H](Cc1ccccc1)C(O)=O JJHBEVZAZXZREW-LFSVMHDDSA-N 0.000 description 1
- XEPSCVXTCUUHDT-AVGNSLFASA-N Arg-Arg-Leu Natural products CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCCN=C(N)N XEPSCVXTCUUHDT-AVGNSLFASA-N 0.000 description 1
- JEXPNDORFYHJTM-IHRRRGAJSA-N Arg-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCCN=C(N)N JEXPNDORFYHJTM-IHRRRGAJSA-N 0.000 description 1
- OKZOABJQOMAYEC-NUMRIWBASA-N Asn-Gln-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OKZOABJQOMAYEC-NUMRIWBASA-N 0.000 description 1
- HPNDKUOLNRVRAY-BIIVOSGPSA-N Asn-Ser-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)N)N)C(=O)O HPNDKUOLNRVRAY-BIIVOSGPSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- 101000708016 Caenorhabditis elegans Sentrin-specific protease Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000032163 Emerging Communicable disease Diseases 0.000 description 1
- 241001428841 Equine influenza virus H3N8 Species 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- MQANCSUBSBJNLU-KKUMJFAQSA-N Gln-Arg-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O MQANCSUBSBJNLU-KKUMJFAQSA-N 0.000 description 1
- VZRAXPGTUNDIDK-GUBZILKMSA-N Gln-Leu-Asn Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N VZRAXPGTUNDIDK-GUBZILKMSA-N 0.000 description 1
- OSCLNNWLKKIQJM-WDSKDSINSA-N Gln-Ser-Gly Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(O)=O OSCLNNWLKKIQJM-WDSKDSINSA-N 0.000 description 1
- RONJIBWTGKVKFY-HTUGSXCWSA-N Gln-Thr-Phe Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCC(=O)N)N)O RONJIBWTGKVKFY-HTUGSXCWSA-N 0.000 description 1
- DTRUBYPMMVPQPD-YUMQZZPRSA-N Gly-Gln-Arg Chemical compound [H]NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O DTRUBYPMMVPQPD-YUMQZZPRSA-N 0.000 description 1
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 1
- MHXKHKWHPNETGG-QWRGUYRKSA-N Gly-Lys-Leu Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O MHXKHKWHPNETGG-QWRGUYRKSA-N 0.000 description 1
- POJJAZJHBGXEGM-YUMQZZPRSA-N Gly-Ser-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)CN POJJAZJHBGXEGM-YUMQZZPRSA-N 0.000 description 1
- PROLDOGUBQJNPG-RWMBFGLXSA-N His-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC2=CN=CN2)N)C(=O)O PROLDOGUBQJNPG-RWMBFGLXSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- NZGTYCMLUGYMCV-XUXIUFHCSA-N Ile-Lys-Arg Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N NZGTYCMLUGYMCV-XUXIUFHCSA-N 0.000 description 1
- PXKACEXYLPBMAD-JBDRJPRFSA-N Ile-Ser-Ser Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)O)N PXKACEXYLPBMAD-JBDRJPRFSA-N 0.000 description 1
- RMJWFINHACYKJI-SIUGBPQLSA-N Ile-Tyr-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N RMJWFINHACYKJI-SIUGBPQLSA-N 0.000 description 1
- ZUWSVOYKBCHLRR-MGHWNKPDSA-N Ile-Tyr-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCCN)C(=O)O)N ZUWSVOYKBCHLRR-MGHWNKPDSA-N 0.000 description 1
- KFKWRHQBZQICHA-STQMWFEESA-N L-leucyl-L-phenylalanine Natural products CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KFKWRHQBZQICHA-STQMWFEESA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 240000000220 Panda oleosa Species 0.000 description 1
- 235000016496 Panda oleosa Nutrition 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 1
- 238000012181 QIAquick gel extraction kit Methods 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- QPFJSHSJFIYDJZ-GHCJXIJMSA-N Ser-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CO QPFJSHSJFIYDJZ-GHCJXIJMSA-N 0.000 description 1
- IOVHBRCQOGWAQH-ZKWXMUAHSA-N Ser-Gly-Ile Chemical compound [H]N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O IOVHBRCQOGWAQH-ZKWXMUAHSA-N 0.000 description 1
- FPCGZYMRFFIYIH-CIUDSAMLSA-N Ser-Lys-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O FPCGZYMRFFIYIH-CIUDSAMLSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- KKPOGALELPLJTL-MEYUZBJRSA-N Thr-Lys-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKPOGALELPLJTL-MEYUZBJRSA-N 0.000 description 1
- DXPURPNJDFCKKO-RHYQMDGZSA-N Thr-Lys-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DXPURPNJDFCKKO-RHYQMDGZSA-N 0.000 description 1
- WPSKTVVMQCXPRO-BWBBJGPYSA-N Thr-Ser-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WPSKTVVMQCXPRO-BWBBJGPYSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000005267 amalgamation Methods 0.000 description 1
- 238000011951 anti-virus test Methods 0.000 description 1
- 108010080488 arginyl-arginyl-leucine Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 108010044056 leucyl-phenylalanine Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a kind of H3N2 types canine influenza virus shuttle intracellular antibody, H3N2 viruses are influenza A, and most important neutralizing antibody comes from surface glycoprotein hemagglutinin（HA）, therefore HA becomes previous main research target；However influenza virus has variability, and the immunological cross-reaction between Different Variation branch is weaker, the antibody of M1 can by with M1 protein bindings, inhibit its activity, the duplication, transcription and release of influenza virus interfered, to play antiviral effect；We select M1 albumen to prepare corresponding antibodies to obtain stable potency, be coupled it with the TAT protein PTD that large biological molecule can be transduceed into cell thus, expressed fusion protein TAT PTD-M1 ScFv, the shuttle antibody for preparing anti-canine influenza virus provides new approach for the treatment of dog influenza.
Description
Technical field
The invention belongs to bioengineering and disease prevention and cure fields, are protected for H3N2 type canine influenza virus more particularly to preparing
Keep antigen shuttle intracellular antibody TAT-2C and this antibody to the antivirus action of H3N2 type canine influenza virus.
Background technology
For a long time, it has been recognized that the influenza virus of canine not various hypotypes of easy infection, therefore dog under natural conditions
It is excluded always except the susceptible range of influenza virus, but virologist in 2004 isolates dog out of Florida dog race body
Influenza virus（Canine influenze virus, CIV）, and after confirming infection of the CIV in each kind of dog, it is this to recognize
It knows the talent and is changed.Hereafter studies have shown that this once matched the influenza virus to raise fear in dog industry and pet-breeder in the U.S.,
The actually variant of equine influenza virus H3N8.Canine influenza virus H3N8 is lethal as a kind of emerging canine pathogenic microorganism
Rate may be up to 8%.This H3N8 dogs influenza is after equine influenza virus makes a variation, to form the ability propagated between horse to dog.
As a kind of epidemic disease of kainogenesis, almost all of dog all lacks immunity to this virus.South Korea researcher report in 2008
The dog influenza of H3N2 hypotypes occurs, and the genetic fragment of several different avian influenza virus is contained in this viral genome, with
The avian influenza virus homology of Southeast Asia prevalence reaches 95.5%-98.9%, and experiment proves that H3N2 subtype influenza virus has been provided with
The ability that dog is propagated, researcher think that this virus is likely to become second popular of canine influenza virus i.e..2006
China is found that the sick dog with flu symptom, and 4 plants of influenza As are separated to from sick dog nose swab, and evolutionary analysis shows 4
The H3N2 CIV germlines branch that 8 genes of a strain are isolated from dog in 2007 with South Korea is close, and artificial liver support proves
Separation strains can infect dog and can directly be propagated between dog, show that fowl source H3N2 CIV have been enter into China.2009-2012 is in
It is separated to CIV in the multiple province ,city and area's disease dogs of state, is found in artificial liver support, being isolated from the influenza virus of dog can not only infect
Dog, moreover it is possible to infecting mouse and pig.Show that H3N2 CIV have adapted to mammal completely, be successfully realized across host propagation,
Exist simultaneously the risk that the span host of new mammal propagates.
Dog influenza is a kind of emerging infectious disease of dog, and different cultivars, all ages and classes dog can all infect, for canine influenza virus
Research foreign countries be only limitted to vaccine research, and the domestic research for canine influenza virus is still in the blank phase, still without corresponding
Prevent and treat the appearance of drug.Dog has special status as companion animals in present human lives.Due to dog and people
And the intimate contact of wild animal, provide more chances to intermediate propagate of influenza virus.Therefore, once there is dog influenza
Be very popular and break out and will will produce serious consequence, it is necessary to accelerate the research and development of CIV related vaccines and medicine.
In the case of viral constantly generation drug resistance, novel antibodies drug becomes reply canine influenza virus and causes potential stream
Feel pandemic effective means.With the development of technique for gene engineering, the development of genetic engineering antibody is very fast, single-chain antibody
It is small with its specificity height, molecular weight, it is simple in structure, it is low compared with parental antibody immunogenicity, maximum it can mitigate in clinical application
The unique advantage of allergy caused by foreign protei has attracted the sight of numerous scientific research persons, technology of preparing to tend to be ripe,
Especially display technique of bacteriophage more improves the screening efficiency of antibody and antibody gene.Single-chain antibody is to disease of viral infection
Treatment will play an important role.
H3N2 viruses are influenza A, and most important neutralizing antibody comes from surface glycoprotein hemagglutinin（HA）, therefore
HA becomes previous main research target.However influenza virus has variability, and the immune friendship between Different Variation branch
Fork reaction is weaker.In view of the influence of virus variation, the antibody based on conservative antigen component can produce different subtype influenza virus
Raw antivirus action.Influenza matrix albumen M1 is the main structural proteins of influenza virus, is located on the inside of virus envelope, passes through
With host cell target protein in conjunction with and participate in and the processes such as duplication, transcription, release of regulation and control virus.M1 protein sequences are conservative, because
This for M1 antibody can by with M1 protein bindings, inhibit its activity, interfere the duplication, transcription and release of influenza virus,
To play antiviral effect.We select M1 albumen to prepare corresponding antibodies to obtain stable potency, not by virus thus
Make a variation the antibody preparation influenced.
M1 albumen is located on the inside of virus envelope, and antibody needs to enter the effect of infection cell competence exertion.Protein transduction domain
（Protein transduction domain,PTD）It is small peptide fragment of the energy mediating proteins across cell membrane, big point can be carried
Son effectively enters cell by biomembrane.The Protein transport that PTD is mediated, can independent of receptor, channel, energy and encytosis
Lipid bilayer to directly act on all types cell completes transmembrane movement, and its cross-film function does not have species spy
It is anisotropic.Since PTD is identified and is identified, there are hundreds of compounds and protein to be entered by Successful transductions different thin
Born of the same parents, and show corresponding bioactivity.In the PTD having found, human immunodeficiency virus-1（HIV-1）TAT protein
PTD is that most study, function exact PTD, Tat PTD can be by the polypeptide being attached thereto, protein and DNA with a kind of concentration
The mode of dependence efficiently and rapidly imports into the cell, and the normal configuration of cell and function are unaffected.Although protein transduction
At present still under study for action, but it will can directly have medicative large biological molecule and be sent into cells play biology effect mechanism
It answers this characteristic to provide new thinking for the biological therapy of disease, thus is received significant attention in medical research field.1997
Year, the discoveries such as Vives, Tat PTD are 11 amino acid positioned at 47~57（YGRKKRRQRRR）, it is one and is rich in
The polypeptide fragment of basic amino acid.The biological transduction properties for seeing TAT PTD, by after the segment and M1 ScFv amalgamation and expressions its
M1 ScFv can be brought to virus infected cell into, targeting prevents it from playing biological function in the M1 albumen of intracellular, inhibits stream
The assembly and release of Influenza Virus, to play antiviral effect.
In conclusion it is target antigen to select canine influenza virus conserved sequence M1 albumen, sieved using dog phage antibody library
The high-affinity single-chain antibody for selecting anti-M1 albumen, it is even with the TAT protein PTD that large biological molecule can be transduceed into cell
Connection, expressed fusion protein TAT PTD-M1 ScFv prepare the shuttle antibody of anti-canine influenza virus, are carried for the treatment of dog influenza
For new approach.
Invention content
The object of the present invention is to provide a kind of H3N2 type dogs streams for H3N2 type canine influenza virus conserved sequence M1 albumen
Influenza Virus shuttle intracellular antibody TAT-2C, this antibody can enter cytosis in target, can be used for controlling for H3N2 type dogs influenza disease
It treats.
H3N2 types canine influenza virus shuttle intracellular antibody TAT-2C, its nucleotide sequence such as sequence table SEQ ID NO.1；
H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C, its amino acid sequence is as shown in sequence table SEQ ID NO. 3；
Applications of the H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C in terms of preparing treatment H3N2 type dog influenza medicines；
The diagnostic kit of H3N2 type canine influenza virus, it includes albumen shown in SEQID NO. 3.
It is A type influenzas the present invention provides a kind of H3N2 types canine influenza virus shuttle intracellular antibody TAT-2C, H3N2 virus
Virus, most important neutralizing antibody come from surface glycoprotein hemagglutinin（HA）, therefore HA becomes previous main research target；So
And influenza virus has variability, and the immunological cross-reaction between Different Variation branch is weaker, the antibody of M1 can lead to
Cross with M1 protein bindings, inhibit its activity, the duplication, transcription and release of influenza virus are interfered, to play antiviral effect；
Thus we select M1 albumen prepare corresponding antibodies with obtain stable potency, by its with large biological molecule can be transduceed into cell
TAT protein PTD coupling, expressed fusion protein TAT PTD-M1 ScFv prepare the shuttle antibody of anti-canine influenza virus, are
The treatment of dog influenza provides new approach.
Description of the drawings
Fig. 1 is M1 protein expressing plasmid pET-SUMO-M1 PCR qualification results；M：DL2000 DNA Marker；1：M1 tables
Up to carrier pET-SUMO-M1 PCR results；
Fig. 2 is expression of results of the PET-SUMO-M1 protein expression engineering bacterias after induction；M：Protein Marker；1：It is negative right
According to；2：Induce thalline ultrasound precipitation；3：Induce thalline ultrasound supernatant；4：Induce full bacterium；
Fig. 3 is M1 albumen after purification；M:Marker;1:SUMO digestions and after purification sample；
Fig. 4 is the PCR qualification results of 10 plants of positive strains；
Fig. 5 is M1-scFv after purification；M:Marker;1:10%-55% saturation degree ammonium sulfate precipitation samples;2:Flow through 3:Purifying
Sample afterwards；
Fig. 6 is the amplification of M1-ScFv genes；M:Marker；1-2:TAT-ScFv PCR products;
Fig. 7 is the induced expression result of recombinant expression plasmid pET-28a-TAT-M1 ScFv；M：Molecular weight of albumen Marker；1:
Negative control；2-3:Recombinant expression plasmid pET-28a-TAT-M1ScFv inductions；
Fig. 8 is the scFv of purifying；M:Marker；
1:TAT-scFv expresses bacterium induced ultrasonic supernatant；
2:Cu2+200 imidazoles elution samples; 3:The TAT-scFv of purifying.
Specific implementation mode
Embodiment 1：Structure, expression and the purifying of M1 albumen of M1 recombinant expression plasmids pET-SUMO-M1
Primer M1P1, M1P2 are designed and synthesized, using dog H3N2 cDNA as template PCR amplifications M1 protein gene, and is cloned into PET-
In SUMO carriers, build plasmid pET-SUMO-M1, be then transferred to T-shot competent cells, the agar plate of the resistance containing kan into
Row preliminary screening.Picking individual colonies are cultivated in LB liquid medium；Plasmid, PCR identifications, production are extracted with plasmid QIAquick Gel Extraction Kit
Object is analyzed through 1% agarose gel electrophoresis, obtains the band of 750 bp or so, size is consistent with the target gene of insertion, and carries out
The measurement of sequence, it was demonstrated that target fragment is correctly inserted into carrier, successfully constructs recombinant plasmid pET-SUMO-M1（See Fig. 1）.
By recombinant plasmid pET-SUMO-M1 conversion expression bacterium e. coli bl21s（DE3）, after IPTG induced expressions, SDS-
PAGE results are shown：Recombinant protein SUMO-M1 has an apparent expression band, size to be consistent with theoretical value at the places 40KD or so, ultrasound
Destination protein is mainly in ultrasonic supernatant afterwards, it was demonstrated that destination protein is expressed with soluble form（See Fig. 2）.
The purifying of M1 albumen takes its supernatant after the cracking of induced expression thalline ultrasound, is precipitated with 20-45% AS, precipitates with PB
(pH 7.0) crosses ion-exchange chromatography after being resuspended（SP FF）, with the PB linear elutions of the Nacl containing 0.5M, collect destination protein and wash
De- peak, crosses Cu2+Column, buffer system are PB+0.5M Nacl, are eluted respectively with 50mM, 150mM imidazoles, destination protein is in 150 mM
In imidazoles eluting peak.It is 50 mM that 150 mM imidazole elutions, which are diluted to imidazole concentration, and SUMO protease, 30 degree of digestions are added
2h.Digestion products cross Cu2+Column, 20mM imidazoles elutes destination protein, then is concentrated with SP FF, obtains M1 egg of the purity 90% or more
In vain, meet the needs of phage antibody library screening（See Fig. 3）.
Embodiment 2：The amplification of phage antibody library
1, structure dog phage antibody library structure
Dog separation of lymphocytes:6 peripheral blood lymphocytes separation of beasle dog, extract total serum IgE, reverse transcription synthesizes cDNA；Expand
Increase VH genes, upstream and downstream are separately added into Nco I, I restriction enzyme sites of Xho；VL genes are expanded, upstream and downstream are separately added into Sal I, Not I
Restriction enzyme site；VH digestions are connected into PIT2 carriers；VL digestions are connected into PIT2 carriers.
2, the carrier electrotransformation e. coli tg1 built is coated with TYE tablets（Containing 100 Portugals μ g/mL Amp+1% of final concentration
Grape sugar）, 37 DEG C are incubated overnight, and random picking monoclonal carries out bacterium solution PCR identifications from tablet, calculate recombination fraction, and estimate library
Hold（Storage capacity=clone's number × extension rate × recombination fraction）And the dog bacteriophage scFv antibody libraries preserved（Storage capacity is 2.5 × 107）It connects
In the 250mL 2 × TY culture mediums for entering preheating（Containing 100 μ g/mL Amp+1% glucose of final concentration）, 37 DEG C of shaken cultivations are extremely
OD600 is 0.4（About 2h）.50mL bacterium solutions are taken to be added 2.0 × 1011Helper phage KM13,37 DEG C of water-bath 30min.By bacterium solution
With 4 DEG C, 3300g centrifuges 20min, precipitation 100mL2 × TY culture mediums (100 μ g/mLAmp+50 μ g/mL Kana+ containing final concentration
0.1% glucose) it is resuspended, 30 DEG C of shaking overnight incubations of 250rpm.4 DEG C of bacterium solution, 3300g 30min will be centrifuged overnight, and collect supernatant
20mL PEG/NaCl solution is added in about 80mL（Final concentration of 20% PEG-6000,2.5mol/L NaCl）, mixing is placed on
Lh on ice.4 DEG C of 3300g centrifuge 30min, and precipitation is resuspended with 4m1 PBS, is mixed well.4 DEG C of 11600g centrifuge 10min, take
Supernatant, 4 DEG C of preservations are carried out at the same time phage titre for screening of phage antibody library and measure.
Embodiment 3：The screening of anti-M1-scFv
The M1 albumen of purifying is antigen coat in 96 hole elisa Plates, and 4 DEG C overnight.Next day abandons supernatant, with 2% Milk-PBS 37
DEG C closing 2h, the phage antibody library of preparation is added（Titre is 1.0 × 1013pfu）, it acutely shakes be incubated 60min at room temperature, it is quiet
Set 60min.After discard liquid, washed 10 times with the PBS containing 0.1%Twenn-20, will be per residual liquid in hole gently after washing
It pats dry, 50 μ L eluents is added per hole（Pancreatin-the PBS of 5mg/mL）, 10min is acutely shaken at room temperature, and wash-out bacteriophage is collected
4 DEG C of preservations.
With the Phage Infection E.coli TG1 under elution, and it is coated on TYE tablets（Containing 100 μ g/mLAmp's and 1%
Glucose）37 DEG C are incubated overnight.Phage library is expanded using helper phage KM13, bacteriophage is recycled by PEG/NaCl.Weight
Multiple above procedure 3 times, totally 4 wheel screening.
Phage Infection after screeningE.ColiHB2151 after induced expression, is identified using ELISA, sets microplate reader measurement
OD values（Wavelength is 490nm）, each sample does diplopore measurement, takes OD average values.Positive colony bacterial strain determines that standard is：OD values are
3 times or more of negative control.
Two Specific PCR primers of synthesis expand scFv full genome segments：
P3: 5’—CAG GAA ACA GCT ATG AC—3’
P4: 5’ —CTA TGC GGC CCC ATT CA—3’
Amplify the segment of 900bp or so, it was demonstrated that obtain complete single-chain antibody (Fig. 4).
Embodiment 4：The expression and purifying of M1-scFv
ELISA positive strains are transferred in 5mL 2 × TY culture mediums（Glucose containing 100 μ g/mLAmp and 1%）, 37 DEG C of cultures
Overnight.Next day, 200 μ L overnight cultures of switching are in 2 × TY culture mediums（Glucose containing 100 μ g/mLAmp and 0.1%）, 37 DEG C
It cultivates to OD600 to 0.9（About 4 h）, final concentration of 1 mmol/L IPTG are added, 30 DEG C of shaken cultivations induce overnight.Next day
Induction bacterium solution 4200rpm is centrifuged into 20 min, takes supernatant, with 10%-55% ammonium sulfate precipitations, 30 mmol/L PB of precipitation
（pH7.2）It is resuspended, the dialysed overnight in PBS, dialysis sample carries out rProtein-A FF affinity chromatographys, and elution samples are saturating with PBS
Overnight, for 12%SDS-PAGE analysis shows that destination protein size is about 31000 Da, scFv purity after purification meets progress for analysis
The requirement of antivirus test.（Fig. 5）
Embodiment 5：Structure, expression and the purifying of TAT-M1 ScFv
Design 2 primers of synthesis：P5, P6 introduce EcoR I, III restriction enzyme sites of Hind respectively, extract M1-ScFv bacterial strain plasmids
（TAT-4F, TAT-2C bacterial strain plasmid）, PCR is carried out as template（Fig. 6）.
P5: 5` GTGAATTCATGAAATACCTATTGCCT 3`
P6: 5` GCAAGCTTCTATGCGGCCCCATTCAG 3`
The amplified production that above-mentioned PCR reactions are recycled using gel electrophoresis, uses EcoR I and III double digestion PCR amplifications of Hind to return respectively
Receive product and carrier pET28a-TAT-GFP, T4 ligase connection PCR product and carrier segments, transformed competence colibacillus Escherichia coli
DH5 α, PCR identify that positive colony, extraction PCR identify correct recombinant plasmid sequencing, the results showed that：TAT-M1 ScFv segments with
Correct reading frame is cloned into expression vector pET-28a.
The PET28a-TAT-M1 ScFv Calcium Chloride Methods of structure are transformed into BL21 (DE3), picking single bacterium colony is inoculated into
Shaken cultivation adds IPTG induced expressions to 0.5 or more bacterium solution OD600 ≈ in LB liquid medium.Induction thalline is collected, is carried out
12%SDS-PAGE is detected, not induce engineering bacteria as negative control, the results show that occurring an apparent table at about 30KDa
Up to band, it is completely the same to be expected size with fusion protein（Fig. 7）.
The purifying of TAT-M1 ScFv takes its supernatant after the cracking of induced expression thalline ultrasound, crosses metal-chelating Cu2+Column delays
Flushing system is PBS (pH7.2), is eluted respectively with 20mM, 200mM imidazoles, destination protein is in 200 mM imidazoles eluting peaks.200
MM imidazole elutions cross affinity column（rProteinA FF）, elution samples are dialysed with PBS, that is, obtain the TAT-M1 of purifying
ScFv（Fig. 8）.
Embodiment 6：The bioactivity of TAT-M1 ScFv detects
Postdigestive mdck cell is spread into 96 porocyte culture plates (3 × 104A cells/well), wait for that cell grows up to single layer suction and abandons training
Base is supported, cell is washed 3 times with DMEM, is separately added into the H3N2 viruses of different dilutions：50 TCID50,100 TCID50,150
TCID50,200 TCID50,250 TCID50,300 TCID50,350 TCID50,400 TCID50, negative control hole are added
PBS, 37 DEG C of incubation 3.5h, abandons extracellular fluid, PBS washes cell 2 times, is separately added into TAT-2C, TAT-4F (10.8 μ g/ of purifying
Hole), positive control adds PBS, 37 DEG C of effect 1.5h, suction to abandon extracellular fluid, and DMEM (containing 2%FBS), 37 DEG C of trainings overnight are added per hole
It supports.Next day does hemagglutination test with overnight culture supernatant.
Hemagglutination test：Culture supernatant is added in reaction plate, 50 holes μ L/, each sample does multiple holes, then is added into every hole
0.85% chicken erythrocyte suspension, 50 holes μ L/, are placed at room temperature for 30min, reaction plate are uprightly observed result.
As a result H3N2 virus activities can be neutralized by showing shuttle intracellular antibody, in TAT-2C, TAT-4F and the effect of H3N2 viruses
Valence is respectively 250TCID50,200TCID500（It is shown in Table 1）.
1 hemagglutination test result table of table
* the TCID50 of H3N2 is 10-4.5/0.1mL。
Sequence table
<110>Military medical research institute of Academy of Military Sciences military affairs veterinary institute
<120>H3N2 type canine influenza virus shuttle intracellular antibodies TAT-2C
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 906
<212> DNA
<213>Dog (Canis lupus familiaris)
<400> 1
tatggtcgta aaaaacgtcg tcagcgtcgt cgtgaattca tgaaatacct attgcctacg 60
gcagccgctg gattgttatt actcgcggcc cagccggcca tggccgaggt gcagctgttg 120
gagtctgggg gaggcttggt acagcctggg gggtccctga gactctcctg tgcagcctct 180
ggattcacct ttagcagcta tgccatgagc tgggtccgcc aggctccagg gaaggggctg 240
gagtgggtct cagatattag taagtctggt tctaagacat cgtacgcaga ctccgtgaag 300
ggccggttca ccatctccag agacaattcc aagaacacgc tgtatctgca aatgaacagc 360
ctgagagccg aggacacggc cgtatattac tgtgcggaaa tgccttctgt ttttgactac 420
tggggccagg gaaccctggt caccgtctcg agcggtggag gcggttcagg cggaggtggc 480
agcggcggtg gcgggtcgac ggacatccag atgacccagt ctccatcctc cctgtctgca 540
tctgtaggag acagagtcac catcacttgc cgggcaagtc agagcattag cagctattta 600
aattggtatc agcagaaacc agggaaagcc cctaagctcc tgatctatga ggcatccaag 660
ttgcaaagtg gggtcccatc aaggttcagt ggcagtggat ctgggacaga tttcactctc 720
accatcagca gtctgcaacc tgaagatttt gcaacttact actgtcaaca gctgaatcat 780
cggcctcaga cgttcggcca agggaccaag gtggaaatca aacgggcggc cgcacatcat 840
catcaccatc acggggccgc agaacaaaaa ctcatctcag aagaggatct gaatggggcc 900
gcatag 906
<210> 2
<211> 906
<212> DNA
<213>Dog (Canis lupus familiaris)
<400> 2
tatggtcgta aaaaacgtcg tcagcgtcgt cgtgaattca tgaaatacct attgcctacg 60
gcagccgctg gattgttatt actcgcggcc cagccggcca tggccgaggt gcagctgttg 120
gagtctgggg gaggcttggt acagcctggg gggtccctga gactctcctg tgcagcctct 180
ggattcacct ttagcagcta tgccatgagc tgggtccgcc aggctccagg gaaggggctg 240
gagtgggtct caggtattaa tagtacgggt aagctgacaa agtacgcaga ctccgtgaag 300
ggccggttca ccatctccag agacaattcc aagaacacgc tgtatctgca aatgaacagc 360
ctgagagccg aggacacggc cgtatattac tgtgcgaaaa ggaggcttct gtttgactac 420
tggggccagg gaaccctggt caccgtctcg agcggtggag gcggttcagg cggaggtggc 480
agcggcggtg gcgggtcgac ggacatccag atgacccagt ctccatcctc cctgtctgca 540
tctgtaggag acagagtcac catcacttgc cgggcaagtc agagcactag cagctattta 600
aattggtatc agcagaaacc agggaaagcc cctaagctcc tgatctataa ggcatcctac 660
ttgcaaagtg gggtcccatc aaggttcagt ggcagtggat ctgggacaga tttcactctc 720
accatcagca gtctgcaacc tgaagatttt gcaacttact actgtcaaca gcggtataat 780
tctcctgcta cgttcggcca aagggaccaa agtggaaatc aaacggcggc cgcacatcat 840
catcaccatc acggggccgc agaacaaaaa ctcatctcag aagaggatct gaatggggcc 900
gcatag 906
<210> 3
<211> 301
<212> PRT
<213>Dog (Canis lupus familiaris)
<400> 3
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Glu Phe Met Lys Tyr
1 5 10 15
Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro
20 25 30
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
35 40 45
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
50 55 60
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
65 70 75 80
Glu Trp Val Ser Asp Ile Ser Lys Ser Gly Ser Lys Thr Ser Tyr Ala
85 90 95
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
100 105 110
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
115 120 125
Tyr Tyr Cys Ala Glu Met Pro Ser Val Phe Asp Tyr Trp Gly Gln Gly
130 135 140
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
145 150 155 160
Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser
165 170 175
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala
180 185 190
Ser Gln Ser Ile Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
195 200 205
Lys Ala Pro Lys Leu Leu Ile Tyr Glu Ala Ser Lys Leu Gln Ser Gly
210 215 220
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
225 230 235 240
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
245 250 255
Gln Leu Asn His Arg Pro Gln Thr Phe Gly Gln Gly Thr Lys Val Glu
260 265 270
Ile Lys Arg Ala Ala Ala His His His His His His Gly Ala Ala Glu
275 280 285
Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
290 295 300
<210> 4
<211> 301
<212> PRT
<213>Dog (Canis lupus familiaris)
<400> 4
Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg Glu Phe Met Lys Tyr
1 5 10 15
Leu Leu Pro Thr Ala Ala Ala Gly Leu Leu Leu Leu Ala Ala Gln Pro
20 25 30
Ala Met Ala Glu Val Gln Leu Leu Glu Ser Gly Gly Gly Leu Val Gln
35 40 45
Pro Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
50 55 60
Ser Ser Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu
65 70 75 80
Glu Trp Val Ser Gly Ile Asn Ser Thr Gly Lys Leu Thr Lys Tyr Ala
85 90 95
Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
100 105 110
Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
115 120 125
Tyr Tyr Cys Ala Lys Arg Arg Leu Leu Phe Asp Tyr Trp Gly Gln Gly
130 135 140
Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
145 150 155 160
Ser Gly Gly Gly Gly Ser Thr Asp Ile Gln Met Thr Gln Ser Pro Ser
165 170 175
Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg Ala
180 185 190
Ser Gln Ser Thr Ser Ser Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly
195 200 205
Lys Ala Pro Lys Leu Leu Ile Tyr Lys Ala Ser Tyr Leu Gln Ser Gly
210 215 220
Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu
225 230 235 240
Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
245 250 255
Gln Arg Tyr Asn Ser Pro Ala Thr Phe Gly Gln Arg Asp Gln Ser Gly
260 265 270
Asn Gln Thr Ala Ala Ala His His His His His His Gly Ala Ala Glu
275 280 285
Gln Lys Leu Ile Ser Glu Glu Asp Leu Asn Gly Ala Ala
290 295 300
Claims (4)
1.H3N2 types canine influenza virus shuttle intracellular antibody TAT-2C, its nucleotide sequence such as sequence table SEQ ID NO.1.
2.H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C, its amino acid sequence such as 3 institutes of sequence table SEQ ID NO.
Show.
3. H3N2 types canine influenza virus shuttle intracellular antibody TAT-2C described in claim 1 is preparing treatment H3N2 type dog influenzas
Application in terms of medicine.
The diagnostic kit of 4.H3N2 type canine influenza virus, it includes albumen shown in SEQID NO. 3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810538741.3A CN108728462B (en) | 2018-05-30 | 2018-05-30 | H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810538741.3A CN108728462B (en) | 2018-05-30 | 2018-05-30 | H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108728462A true CN108728462A (en) | 2018-11-02 |
| CN108728462B CN108728462B (en) | 2022-02-22 |
Family
ID=63936782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810538741.3A Active CN108728462B (en) | 2018-05-30 | 2018-05-30 | H3N2 type canine influenza virus shuttle intracellular antibody TAT-2C |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108728462B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111732661A (en) * | 2020-06-11 | 2020-10-02 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-7B and application thereof |
| CN111748568A (en) * | 2020-06-11 | 2020-10-09 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F-mFc and application thereof |
| CN111778269A (en) * | 2020-06-11 | 2020-10-16 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102558348A (en) * | 2012-03-09 | 2012-07-11 | 中国农业科学院上海兽医研究所 | Single-chain antibody for resisting influenza viruses, preparation method for single-chain antibody, application of single-chain antibody |
| CN104293739A (en) * | 2014-10-11 | 2015-01-21 | 南京农业大学 | Single clone antibody aiming at H3N2 dog flu virus HA2 protein |
| CN104911150A (en) * | 2015-05-27 | 2015-09-16 | 华南农业大学 | Establishment method of monoclonal antibody hybridoma cell strain for H3N2 canine influenza virus and preparation method and application of monoclonal antibody of monoclonal antibody hybridoma cell strain |
| CN106381288A (en) * | 2016-08-31 | 2017-02-08 | 广州优迪生物科技有限公司 | Anti-H3N2 subtype canine influenza virus nucleoprotein monoclonal antibody hybridoma 2D10, and monoclonal antibody |
| CN107034197A (en) * | 2017-05-15 | 2017-08-11 | 江苏省农业科学院 | canine influenza virus monoclonal antibody hybridoma cell strain F112 and application |
-
2018
- 2018-05-30 CN CN201810538741.3A patent/CN108728462B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102558348A (en) * | 2012-03-09 | 2012-07-11 | 中国农业科学院上海兽医研究所 | Single-chain antibody for resisting influenza viruses, preparation method for single-chain antibody, application of single-chain antibody |
| CN104293739A (en) * | 2014-10-11 | 2015-01-21 | 南京农业大学 | Single clone antibody aiming at H3N2 dog flu virus HA2 protein |
| CN104911150A (en) * | 2015-05-27 | 2015-09-16 | 华南农业大学 | Establishment method of monoclonal antibody hybridoma cell strain for H3N2 canine influenza virus and preparation method and application of monoclonal antibody of monoclonal antibody hybridoma cell strain |
| CN106381288A (en) * | 2016-08-31 | 2017-02-08 | 广州优迪生物科技有限公司 | Anti-H3N2 subtype canine influenza virus nucleoprotein monoclonal antibody hybridoma 2D10, and monoclonal antibody |
| CN107034197A (en) * | 2017-05-15 | 2017-08-11 | 江苏省农业科学院 | canine influenza virus monoclonal antibody hybridoma cell strain F112 and application |
Non-Patent Citations (2)
| Title |
|---|
| ANDREA L.J.MARSCHALL等: "Targeting antibodies to the cytoplasm", 《MABS.》 * |
| 邱冬等: "H3N2亚型犬流感病毒单链抗体的制备", 《中国兽医科学》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111732661A (en) * | 2020-06-11 | 2020-10-02 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-7B and application thereof |
| CN111748568A (en) * | 2020-06-11 | 2020-10-09 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F-mFc and application thereof |
| CN111778269A (en) * | 2020-06-11 | 2020-10-16 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F and application thereof |
| CN111778269B (en) * | 2020-06-11 | 2022-05-17 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F and application thereof |
| CN111748568B (en) * | 2020-06-11 | 2022-05-31 | 军事科学院军事医学研究院军事兽医研究所 | anti-H5N 1 virus entry antibody PTD-3F-mFc and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108728462B (en) | 2022-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111560074B (en) | Novel coronavirus S protein single-region subunit nano vaccine based on helicobacter pylori ferritin | |
| Corbett et al. | Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages | |
| Mittler et al. | Hantavirus entry: Perspectives and recent advances | |
| Siriwattananon et al. | Development of plant-produced recombinant ACE2-Fc fusion protein as a potential therapeutic agent against SARS-CoV-2 | |
| CN103172749B (en) | Preparation of African swine fever protein engineering vaccine | |
| CN105934441A (en) | A novel sars immunogenic composition | |
| CN108728462A (en) | H3N2 type canine influenza virus shuttle intracellular antibodies TAT-2C | |
| CN108728461A (en) | H3N2 type canine influenza virus shuttle intracellular antibodies TAT-4F | |
| CN106661091A (en) | Influenza virus vaccines and uses thereof | |
| CN113150083B (en) | Recombinant avian influenza subunit vaccine and preparation method thereof | |
| CN110551187B (en) | Chemically synthesized H7N9 avian influenza virus NA protein extracellular region antigen segment, preparation method and application | |
| CN104203272A (en) | Composite antigenic sequences and vaccines | |
| CN111655284A (en) | Influenza virus vaccines and uses thereof | |
| CN102210860B (en) | Mycobacterium tuberculosis TB10.4-F1 fusion protein vaccine and preparation method thereof | |
| CN107108755A (en) | By being fused to the recombinant protein multimerization that the sequence from lamprey is carried out | |
| CN106279431B (en) | A kind of pig circular ring virus subunit inactivated vaccine | |
| CN101497909B (en) | Method for preparing anti-A type botulinus toxin immunoglobulin antibody | |
| KR20070102429A (en) | Using a reverse genetic engineering platform to produce protein vaccine and protein vaccine of avian influenza virus | |
| CN108715866A (en) | A kind of recombinant viral vector, vaccine and the preparation method and application thereof | |
| CN102058881A (en) | Gene recombinant vaccine for preventing enterovirus 71 infection and preparation method thereof | |
| Li et al. | A novel variable antibody fragment dimerized by leucine zippers with enhanced neutralizing potency against rabies virus G protein compared to its corresponding single-chain variable antibody fragment | |
| CN109053896A (en) | A kind of pig circular ring virus bivalent genetic engineering vaccine | |
| CN101134781A (en) | Recombinant fusion protein carrying anthrax protective antigens epitope inserted to hepatitis B core antigen protein or its fragment and uses thereof | |
| CN113121672A (en) | Soluble prokaryotic expression and purification method of cat interferon gamma and application | |
| CN112316130A (en) | SARS-CoV2 mucosal immune vaccine and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |